Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate

AAPS PharmSciTech

Volumn 11, Issue 2, 2010, Pages 818-825

  Collier, Jarrod W ^a,b   Shah, Rakhi B ^a   Gupta, Abhay ^a   Sayeed, Vilayat ^a   Habib, Muhammad J ^b   Khan, Mansoor A ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b HOWARD UNIVERSITY   (United States)

Author keywords

Excipients; Formulation; Levothyroxine sodium pentahydrate; Moisture sorption; Stability

Indexed keywords

CROSPOVIDONE; LEVOTHYROXINE SODIUM; POVIDONE; SODIUM LAUREL SULFATE; SODIUM SULFATE; UNCLASSIFIED DRUG; EXCIPIENT; THYROXINE;

ADSORPTION; ARTICLE; CONTROLLED STUDY; DEAMINATION; DEIODINATION; DESICCATION; DRUG DEGRADATION; DRUG MARKETING; DRUG POTENCY; DRUG STABILITY; HIGH TEMPERATURE; HUMIDITY; LOW TEMPERATURE; MOISTURE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ROOM TEMPERATURE; SHELF LIFE; SOLID STATE; TABLET FORMULATION; TEMPERATURE DEPENDENCE; CHEMISTRY; DRUG FORMULATION; DRUG SCREENING; PROCEDURES; SOLUBILITY; TEMPERATURE;

DRUG COMPOUNDING; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; EXCIPIENTS; SOLUBILITY; TEMPERATURE; THYROXINE;

EID: 77954815304     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-010-9434-8     Document Type: Article

References (23)

1. Goodman L, Gilman A. The pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001.
2. Rhodes C. Regulatory aspects of the formulation and evaluation of levothyroxine tablets. Clin Res Regul Aff. 1998;15:173-86.
3. FDA. Regulatory history and current issues. Health & Human Services; 2006.
4. Post A, Warren R. Sodium levothyroxine. In: Florey K, editor. Analytical profiles of drug substances. New York: Academic Press; 1976. p. 226-81.
5. Won CM. Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm Res. 1992;9:131-7.
6. Kazemifard AG, Moore DE, Aghazadeh A. Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection. J Pharm Biomed Anal. 2001;25:697-711.
7. Wortsman J, Papadimitriou DC, Borges M, Defesche CL. Thermal inactivation of L-thyroxin. Clin Chem. 1989;35:90-2.
8. Patel H, Stalcup A, Dansereau R, Sakr A. The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets. Int J Pharm. 2003;264:35-43.
9. Das Gupta V, Odom C, Bethea C, Plattenburg J. Effect of excipients on the stability of levothyroxine sodium tablets. J Clin Pharm Ther. 1990;15:331-6.
10. Burger A, Griesser UJ. Physical stability, hygroscopicity and solubility of succinyl-sulfathiazole. Eur J Pharm Biopharm. 1991;37:18-24.
11. Morris KR, Griesser UJ, Eckhardt CJ, Stowell JG. Theoretical approaches to physical transformations of active pharmaceutical ingredients during manufacturing processes. Adv Drug Deliv Rev. 2001;48:91-114.
12. Otsuka M, Hasegawa H, Matsuda Y. Effect of polymorphic transformation during the extrusion-granulation process on the pharmaceutical properties of carbamazepine granules. Chem Pharm Bull. 1997;45:894-8.
13. Phadnis NV, Suryanarayanan R. Polymorphism in anhydrous theophylline-implications on the dissolution rate of theophylline tablets. J Pharm Sci. 1997;86:1256-63.
14. Monkhouse DC. Stability aspects of preformulation and formulation of solid pharmaceuticals. Drug Dev Ind Pharm. 1984;10:1373-412.
15. Kandarapu R, Grover V, Chawla H P S, Garg S. Evaluation of the compatibility of ketorolac tromethamine with selected polymers and common tablet excipients by thermal and isothermal stress testing. S T P Pharma Sci. 2001;11:449-57.
16. Serajuddin AT, Thakur AB, Ghoshal RN, Fakes MG, Ranadive SA, Morris KR et al. Selection of solid dosage form composition through drug-excipient compatibility testing. J Pharm Sci. 1999;88:696-704.
17. Gu L, Strickley RG, Chi LH, Chowhan ZT. Drug-excipient incompatibility studies of the dipeptide angiotensin-converting enzyme inhibitor, moexipril hydrochloride: dry powder vs wet granulation. Pharm Res. 1990;7:379-83.
18. Shah RB, Bryant A, Collier J, Habib MJ, Khan MA. Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients. Int J Pharm. 2008;360:77-82.
19. Kopelman SH, Augsburger LL. Excipient compatibility study of Hypericum perforatum extract (St. John's Wort) using similarity metrics to track phytochemical profile changes. Int J Pharm. 2002;237:35-46.
20. Patel N, Patel I, Cutie A, Wadke D, Monkhouse D, Reier G. The effect of selected direct compression excipients on the stability of aspirin as a model hydrolysable drug. Drug Dev Ind Pharm. 1998;14:77-98.
21. van Dooren AA, Duphar BV. Design for drug-excipient interaction studies. Drug Dev Ind Pharm. 1983;9:43-55.
22. Kowalski J, Kalb O, Joshi YM, Serajuddin A T M. Application of melt granulation technology to enhance stability of a moisture sensitive immediate-release drug product. Int J Pharm. 2009;381:56-61.
23. Andre A, Domanig R, Riemer E, Moser H, Groeppelin A. Identification and thermal degradation products of L-triiodothyroxine sodium (liothyroxine sodium) by reversed phase HPLC with photodiode-array UV and mass spectrometric detection. J Chromatogr A. 1996;725:287-94.